Encompass Wealth Advisors LLC Sells 1,997 Shares of Johnson & Johnson (NYSE:JNJ)

Encompass Wealth Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 37.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,335 shares of the company’s stock after selling 1,997 shares during the period. Encompass Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $482,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Iron Horse Wealth Management LLC increased its position in shares of Johnson & Johnson by 33.2% during the fourth quarter. Iron Horse Wealth Management LLC now owns 3,296 shares of the company’s stock valued at $477,000 after acquiring an additional 822 shares in the last quarter. Consolidated Portfolio Review Corp raised its stake in shares of Johnson & Johnson by 347.8% in the fourth quarter. Consolidated Portfolio Review Corp now owns 16,552 shares of the company’s stock worth $2,394,000 after purchasing an additional 12,856 shares during the last quarter. Eagle Ridge Investment Management boosted its position in shares of Johnson & Johnson by 1.7% during the fourth quarter. Eagle Ridge Investment Management now owns 38,773 shares of the company’s stock valued at $5,607,000 after buying an additional 665 shares during the last quarter. Citrine Capital LLC purchased a new position in Johnson & Johnson in the 4th quarter worth about $1,429,000. Finally, Telos Capital Management Inc. lifted its stake in Johnson & Johnson by 1.3% during the 4th quarter. Telos Capital Management Inc. now owns 54,296 shares of the company’s stock valued at $7,852,000 after acquiring an additional 705 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JNJ. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Raymond James reduced their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company dropped their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Finally, Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $153.10 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $368.61 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock’s 50 day simple moving average is $147.42 and its two-hundred day simple moving average is $156.08.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.